Company
Rhythm
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
3
Originals and new uses
Phase 3 trials
12
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)Pivotal-lookingRecruiting
Rhythm Pharmaceuticals, Inc.Industry
NCT06760546 · 39 participants (planned) · Start Sep 23, 2025 · Primary completion Mar 13, 2027
Drug: Setmelanotide; Placebo · For: Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form; Septo-Optic Dysplasia and 3 more
Sites: Birmingham, Alabama; Aurora, Colorado; Chicago, Illinois · 11 sites in all
Marketed drugs (1)
Newest FDA action first.
- Imcivree Setmelanotide Acetate · 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.